prinaberel
Small moleculeexperimental
Prinaberel is a synthetic, nonsteroidal, and highly selective agonist of the ERβ subtype of the estrogen receptor. It is used in scientific research to elucidate the role of the ERβ receptor. Studies have indicated that selective ERβ agonists like prinaberel could be useful in the clinical treatment of a variety of medical conditions including inflammatory bowel disease, rheumatoid arthritis, endometriosis, and sepsis. Accordingly, prinaberel either was or still is under investigation by Wyeth for the treatment of some of these conditions. — Wikipedia
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2004 (NCT00245947)
Timeline
Indications
Mechanism of action
- Estrogen receptor betaAGONIST
ESR2 agonist
Development discontinued after Ph2 trial
Chemistry & pharmacology
Loading structure…
SMILES
C=Cc1cc(O)cc2nc(-c3ccc(O)c(F)c3)oc12- Mol. weight
- 271.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPrinaberel ↗
- ChEMBLCHEMBL450940 ↗
Also known as
- erb041
- erb 041
- erb-041
- erb-041
- erb-041
- erb-041
- pf-00913086
- pf-00913086
- prinaberel
- prinaberel
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00275379 | N/A | Aug 1, 2006 | Pfizer, Wyeth |
| NCT00434187 | Phase 1 | Aug 1, 2006 | Pfizer, Wyeth |
| NCT00316459 | Phase 1 | May 1, 2006 | Pfizer, Wyeth |
| NCT00318500 | Phase 2 | May 1, 2006 | Pfizer, Wyeth |
| NCT00141830 | Phase 2 | Aug 1, 2005 | Pfizer, Wyeth |
| NCT00110487 | Phase 2 | Jan 1, 2005 | Pfizer, Wyeth |
| NCT00245947 | Phase 1 | Apr 1, 2004 | Pfizer, Wyeth |
Showing 7 of 7 trials
Page 1 / 1